Cheryl Barton, a biochemist who runs the consultancy PharmaVision in West Sussex, UK, says this outsourcing represents a sea change from the old way of doing things.
"When I worked at Merck years ago, it was one of those companies that didn't outsource anything at all," she
"The market is demanding controlled release technology," says Cheryl Barton, director of the Chichester, UK - based biomedical consultancy Pharmavision.
notes that patients like the convenience of once-a-day pills as opposed to having to remember to take multiple doses morning, noon and night.
According to a 2009 Pharmavision report, medications using controlled release technology generate annual sales in excess of $20 billion.
And although the majority of such sales currently derive from pill formulations, injectables are on the rise, Barton
"There's a price to be paid for the convenience of those products," says Barton
notes, has resulted in uneven adoption of time-release medications from country to country.
"One of the biggest markets for this has been the US," she
explains, but European countries with nationalized health systems seem less keen to pay for such medications."
With concern growing over the side effects of RNAi-based treatments, firms must now "conclusively prove the mechanism of action of their products", says PharmaVision consultant Cheryl Barton.
"I believe they have up to 90% of the patents," says analyst/consultant Cheryl Barton.
Many of them are launching initiatives that combine in vitro diagnostics with therapeutic solutions in one procedure, according to Dr Cheryl Barton, founder of U.K. consultant firm PharmaVision.
Targeted carrier systems represented about half of the $6.5 billion market for advanced drug delivery in 2006, reported Barton